(DYN) Dyne Therapeutics - Ratings and Ratios
Muscle, Oligonucleotide, Therapy
DYN EPS (Earnings per Share)
DYN Revenue
Description: DYN Dyne Therapeutics
Dyne Therapeutics Inc (NASDAQ:DYN) is a biotechnology company listed on the NASDAQ stock exchange, categorized under the biotechnology sub-industry according to the GICS classification. The companys stock performance and financial health are critical indicators for investors.
To evaluate the investment potential of DYN, its essential to examine key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash burn rate. The companys market capitalization stands at approximately $1.43 billion, indicating its size and market presence. However, the absence of a price-to-earnings (P/E) ratio, due to likely negative earnings, suggests that the company is not yet profitable.
The return on equity (RoE) of -64.12% signifies substantial losses relative to shareholder equity, a common trait among growth-stage biotech companies investing heavily in R&D. Investors should monitor the companys cash reserves, burn rate, and upcoming milestones, such as clinical trial results or regulatory approvals, which can significantly impact stock performance.
Economic drivers for DYN include the demand for innovative treatments in the biotechnology sector, the success of its pipeline assets, and the overall market sentiment towards biotech stocks. The companys ability to advance its pipeline, achieve clinical milestones, and eventually bring products to market will be crucial for its long-term success and stock performance.
Investors should also consider the competitive landscape of the biotechnology industry, the companys intellectual property position, and potential partnerships or collaborations that could impact its financials and stock price. A thorough analysis of these factors will help investors make informed decisions about investing in DYN.
DYN Stock Overview
| Market Cap in USD | 1,871m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-09-17 |
DYN Stock Ratings
| Growth Rating | -35.8% |
| Fundamental | 24.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -67.7% |
| Analyst Rating | 4.43 of 5 |
DYN Dividends
Currently no dividends paidDYN Growth Ratios
| Growth Correlation 3m | 62.5% |
| Growth Correlation 12m | -80.1% |
| Growth Correlation 5y | 0.6% |
| CAGR 5y | -1.25% |
| CAGR/Max DD 3y | -0.01 |
| CAGR/Mean DD 3y | -0.05 |
| Sharpe Ratio 12m | -0.96 |
| Alpha | -67.22 |
| Beta | 0.209 |
| Volatility | 72.72% |
| Current Volume | 2028.3k |
| Average Volume 20d | 2028.3k |
| Stop Loss | 12.3 (-6.5%) |
| Signal | -0.52 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-412.9m TTM) > 0 and > 6% of Revenue (6% = 94.3k TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -17.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.8k% (prev 20.1k%; Δ 21.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.49 (>3.0%) and CFO -359.6m > Net Income -412.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 16.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (113.9m) change vs 12m ago 23.10% (target <= -2.0% for YES) |
| Gross Margin 10.81% (prev 48.52%; Δ -37.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.20% (prev 0.46%; Δ -0.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4696 (EBITDA TTM -439.5m / Interest Expense TTM 94.0k) >= 6 (WARN >= 3) |
Altman Z'' -11.00
| (A) 0.90 = (Total Current Assets 698.0m - Total Current Liabilities 41.5m) / Total Assets 729.0m |
| (B) -1.61 = Retained Earnings (Balance) -1.18b / Total Assets 729.0m |
| warn (B) unusual magnitude: -1.61 — check mapping/units |
| (C) -0.57 = EBIT TTM -441.4m / Avg Total Assets 777.4m |
| (D) -7.46 = Book Value of Equity -1.18b / Total Liabilities 157.5m |
| Total Rating: -11.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.65
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -22.84% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.18 = 2.48 |
| 5. Debt/Ebitda -0.24 = -2.50 |
| 6. ROIC - WACC -72.45% = -12.50 |
| 7. RoE -64.12% = -2.50 |
| 8. Rev. Trend 12.59% = 0.63 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -38.45% = -0.96 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of DYN shares?
Over the past week, the price has changed by -1.13%, over one month by +5.20%, over three months by -4.85% and over the past year by -61.77%.
Is Dyne Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DYN is around 10.83 USD . This means that DYN is currently overvalued and has a potential downside of -17.64%.
Is DYN a buy, sell or hold?
- Strong Buy: 7
- Buy: 6
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.4 | 168.8% |
| Analysts Target Price | 35.4 | 168.8% |
| ValueRay Target Price | 11.9 | -9.9% |
Last update: 2025-09-13 04:34
DYN Fundamental Data Overview
CCE Cash And Equivalents = 683.9m USD (Cash And Short Term Investments, last quarter)
P/B = 3.28
P/EG = 0.19
Beta = 1.103
Revenue TTM = 1.57m USD
EBIT TTM = -441.4m USD
EBITDA TTM = -439.5m USD
Long Term Debt = 98.8m USD (from longTermDebt, last quarter)
Short Term Debt = 5.00m USD (from shortTermDebt, last quarter)
Debt = 103.8m USD (Calculated: Short Term 5.00m + Long Term 98.8m)
Net Debt = -462.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.29b USD (1.87b + Debt 103.8m - CCE 683.9m)
Interest Coverage Ratio = -4696 (Ebit TTM -441.4m / Interest Expense TTM 94.0k)
FCF Yield = -22.84% (FCF TTM -294.7m / Enterprise Value 1.29b)
FCF Margin = -18.7k% (FCF TTM -294.7m / Revenue TTM 1.57m)
Net Margin = -26.3k% (Net Income TTM -412.9m / Revenue TTM 1.57m)
Gross Margin = 10.81% ((Revenue TTM 1.57m - Cost of Revenue TTM 1.40m) / Revenue TTM)
Tobins Q-Ratio = -1.10 (set to none) (Enterprise Value 1.29b / Book Value Of Equity -1.18b)
Interest Expense / Debt = 0.09% (Interest Expense 94.0k / Debt 103.8m)
Taxrate = 21.0% (US default)
NOPAT = -441.4m (EBIT -441.4m, no tax applied on loss)
Current Ratio = 16.83 (Total Current Assets 698.0m / Total Current Liabilities 41.5m)
Debt / Equity = 0.18 (Debt 103.8m / last Quarter total Stockholder Equity 571.4m)
Debt / EBITDA = -0.24 (Net Debt -462.8m / EBITDA -439.5m)
Debt / FCF = -0.35 (Debt 103.8m / FCF TTM -294.7m)
Total Stockholder Equity = 643.9m (last 4 quarters mean)
RoA = -56.64% (Net Income -412.9m, Total Assets 729.0m )
RoE = -64.12% (Net Income TTM -412.9m / Total Stockholder Equity 643.9m)
RoCE = -59.43% (Ebit -441.4m / (Equity 643.9m + L.T.Debt 98.8m))
RoIC = -66.02% (NOPAT -441.4m / Invested Capital 668.7m)
WACC = 6.44% (E(1.87b)/V(1.97b) * Re(6.79%)) + (D(103.8m)/V(1.97b) * Rd(0.09%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 7.42%
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -294.7m)
Revenue Correlation: 12.59 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -1131
EPS Correlation: -38.45 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 2.74
Additional Sources for DYN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle